Antioxidant Carbocysteine Treatment in Obstructive Sleep Apnoea Syndrome
Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
Obstructive sleep apnoea syndrome (OSAS) is characterised by repeated episodes of upper
airway occlusion during sleep.It can cause cycles of hypoxia reoxygenation. And it was
postulated that intermittent hypoxia seems to resemble ischemia-reperfusion.Many study
suggest that ischemia-reperfusion represents an oxidative stress causing increased generation
of reactive oxygen species, especially superoxide anions.It is one of the most important
mechanisms of cardiovascular diseases, including hypertension, coronary artery disease and
cerebrovascular accident complication with OSAS.So many individuals approve OSAS is an
Oxidative Stress disease.
Continuous positive airway pressure (CPAP) is the first-line of treatment method in
moderate/severe OSA.But poor adherence to CPAP treatment is very common.The failure rate with
CPAP treatment is more than 50%.So we are searching a new treatment for that patients.
Carbocysteine is a antioxidant.It can not only scavenges the free radicals but also
replenishes glutathione(GSH)which is has double antioxidant capacity. However, Carbocysteine
is cheaper than other which has double antioxidant capacity drugs,such as
N-acetylcysteine.The purpose is to evaluate efficacy of oral intake of Antioxidant
Carbocysteine witch can reduce oxidative stress and improve the symptom of OSAS.It recover
the imbalance in the oxidant-anti-oxidant status may reduce cardiovascular abnormalities in
Patients with OSAS.